Small cell lung cancer: was the care up to standard?

Small cell lung cancer moves fast, and its guidelines are short and firm. There are fewer decision points than in other cancers, which means each one carries more weight, and a miss is easier to spot in the record.

The decisions that matter

• Stage classification. Small cell is staged in two bins: limited (confined to one side of the chest, treatable within a single radiation field) and extensive (everything else). The bin determines the entire plan, so the record has to establish it.
• The chemotherapy backbone. First-line treatment is built on a platinum drug (cisplatin or carboplatin) plus etoposide. It has been the backbone for decades, and a first-line record showing something else needs an explanation.
• Immunotherapy in extensive-stage disease. The guidelines add an immunotherapy drug, atezolizumab or durvalumab, to first-line chemotherapy for extensive-stage disease. A patient started on chemotherapy alone, with immunotherapy never mentioned, is being treated to an older standard.
• Chest radiation in limited-stage disease. Limited-stage treatment pairs the chemotherapy with radiation to the chest, given concurrently when the patient can tolerate it. That combination is what makes limited-stage disease potentially curable. A limited-stage record with no radiation oncology involvement is a serious gap.

What a deviation looks like

Extensive-stage disease treated with chemotherapy alone while immunotherapy goes unmentioned. A limited-stage patient never referred for radiation. A first line built on something other than platinum plus etoposide with no reason documented. Each finding cites its guideline page so a clinician or attorney can pull the source directly.